Viragen Inc. Granted Multiferon®’s Exclusive Marketing Rights in Australia and New Zealand to Orphan Australia
Though complete financial terms were not disclosed, the said agreement provides Viragen with an up-front license fee, and additional milestone payments to be paid upon receipt of reimbursement authorization for Multiferon® in
Viragen has estimated the agreement to be valued at approximately $10 to 15 million (USD) per year for the company, pending regulatory approval and reimbursement authorization, and based on revenue forecasts for peak year sales. Multiferon® is an alpha interferon drug product that contains a unique mixture of multiple subtypes of human interferon (a1, a2, a8, a10, a14, a21) and was approved in Source: Viragen, Inc.
Comment Preview